Subject: Transfer of Company''s Active Pharmaceuticals Ingredient (API) Business. Further to the earlier intimation dated September 25, 2018, announcing the shareholder approval for the above transaction, we hereby advise that a Business Purchase Agreement for transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company, has been executed on October 9, 2018. The transaction is expected to be completed in the next 2-3 months. Dear Sirs, Subject: Completion of transfer of Company''s Active Pharmaceuticals Ingredient (API) Business. Further to the earlier intimation dated October 9, 2018, we hereby inform you that transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company, has been completed on December 31, 2018. Request you to kindly take note of the same. Thanking You. (As Per BSE Announcement Dated on 01.01.2019)